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Abstract
Despite the use of combination antiretroviral drugs for the treatment of HIV-1 infection, the emergence of drug resistance re-
mains a problem. Resistance may be conferred either by a single mutation or a concerted set of mutations. The involvement
of multiple mutations can arise due to interactions between sites in the amino acid sequence as a consequence of the need to
maintain protein structure. To better understand the nature of such epistatic interactions, we reconstructed the ancestral se-
quences of HIV-1’s Pol protein, and traced the evolutionary trajectories leading to mutations associated with drug resistance.
Using contemporary and ancestral sequences we modelled the effects of mutations (i.e. amino acid replacements) on protein
structure to understand the functional effects of residue changes. Although the majority of resistance-associated sequences
tend to destabilise the protein structure, we find there is a general tendency for protein stability to decrease across HIV-1’s
evolutionary history. That a similar pattern is observed in the non-drug resistance lineages indicates that non-resistant muta-
tions, for example, associated with escape from the immune response, also impacts on protein stability. Maintenance of opti-
mal protein structure therefore represents a major constraining factor to the evolution of HIV-1.
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1. Introduction
HIV-1 is the etiologic agent for Acquired Immunodeficiency
Syndrome (AIDS) (Barre-Sinoussi et al. 1983; Gallo et al. 1983)
and is estimated to have been in the human population since at
least the 1920s (Faria et al. 2014). Approximately 35 million peo-
ple are currently infected with HIV-1, and since its discovery
over 30 years ago, there have been over 39 million deaths
(Gulland 2014). AIDS is characterized by progressive immune
system failure followed by loss of immune function, and subse-
quent development of cancers and opportunistic infections that
lead to death of infected individuals (Gallo and Montagnier
2003). Treating infected individuals effectively has been difficult
due to the presence of latent virus and reservoirs necessitating
continued therapy (Lorenzo-Redondo et al. 2016), the evolution
of drug resistant HIV-1 strains and failure of vaccine initiatives
(Greene 2007).
Highly active antiretroviral therapy (HAART) delays the pro-
gression to disease, prolonging the lives of infected individuals,
and reducing the transmission of the virus (Cooper and Merigan
1996; Rhee et al. 2003; Shafer 2006; Falco et al. 2008). The use of
antiretroviral drugs has been associated with the accumulation
of missense mutations causing amino acid replacements that
lead to the emergence of drug resistance. These changes are ex-
amples of adaptive viral evolution: typically selection pressure
arising from the host immune system or the presence of antire-
troviral drugs (Pillay et al. 2000; Rambaut et al. 2004). Drugs fall
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into several classes: nucleoside reverse transcriptase inhibitors
(NRTIs) and non-nucleoside reverse transcriptase inhibitors
(NNRTIs), both targeting reverse transcriptase, other inhibitors
targeting the protease or integrase (Furman and Barry 1988;
Reeves and Piefier 2005; Evering and Markowitz 2008), or fusion
and entry inhibitors that are designed to block cell entry
(MacArthur and Novak 2008; Eggink et al. 2010). Unfortunately,
resistance to all of these drug classes has been observed.
Resistant strains are usually fixed in the population as a re-
sult of competition between variants of HIV-1 in the context of
drug selection (Ribeiro and Bonhoeffer 2000). Despite a high de-
gree of sequence diversity, the virus is subject to constraints on
its evolution. These constraints arise principally from the re-
quirement of the viral proteins to produce stable, soluble struc-
tures that perform the necessary molecular functions for viral
replication and persistence (Woo et al. 2010; Snoeck et al. 2011;
Williams et al. 2011). Co-evolution within individual HIV-1 pro-
teins has been identified as an important constraint in the evo-
lution of immune escape (Dahirel et al. 2011). Similarly, HIV-1
drug resistance can be restricted by epistatic interactions
(Bonhoeffer et al. 2004; Chen et al. 2004; Hinkley et al. 2011),
which apparently arise predominantly from residues that are in
close proximity in the protein structure (Hinkley et al. 2011).
The majority of mutations that can possibly occur in protein
structure (for all species) have been shown to be destabilizing
and, hence, deleterious with only about 5% having a stabilizing
effect (DDG<1 kcal/mol) (Tokuriki et al. 2007). That the major-
ity of possible changes result in non-functional proteins there-
fore poses a major constraint on possible future adaptations
(Tokuriki and Tawfik 2009). As a consequence it is expected that
protein stability will constrain possible change, with increased
stability a pre-requisite for significant evolutionary change, that
is, the acceptance of otherwise deleterious destabilizing amino
acid replacements (Bloom et al. 2006; Tokuriki and Tawfik 2009).
For example, a small number of protease residue replacements
have been characterized experimentally (Chang and Torbett
2011), demonstrating the importance of ‘permissive’ changes
for the evolution of otherwise deleterious replacements, and
the importance of residue replacements away from the ac-
tive site in altering binding affinity for protease inhibitors
(Muzammil et al. 2003).
Here, we investigate the importance of this stability mecha-
nism in the HIV-1 pandemic by analysing relatively large sets of
viral sequences in the context of three-dimensional structures
of Pol proteins and their evolutionary history. By reconstructing
ancestral sequences and mapping amino acid replacements to
the protein structures, we can characterize the likely effects of
replacements on protein structure, stability and function.
Although the majority of resistance-associated sequences
destabilise the protein structure, this is the general trend for
many residue changes. Specifically, comparing HIV-1’s more re-
cent evolutionary history with inferred ancestral sequences,
there has been a significant decrease in protein stability. We
discuss the implications of these results for the fitness of circu-
lating HIV-1.
2. Results
2.1 Phylogenetic analysis
To determine the effect of drug selection on the emergence of
resistance, we aligned subtype B sequences from the Los
Alamos National Laboratory database that were dated as either
pre-1996 or 1996 onwards, as this is the year that HAART was
widely introduced. We assume the sequences sampled post-
1996 to be from patients receiving HAART, since it is likely that
all patients who contributed samples for sequencing in the USA
and Europe (where subtype B is mostly found) would be receiv-
ing drug treatment. Maximum likelihood trees for the protease
protein (Fig. 1A) show that in the absence of drug treatment, se-
quences containing amino acid replacements known to confer
drug resistance, as expected, are sparse and scattered through-
out the phylogenetic tree. A similar pattern is observed for the
reverse transcriptase proteins (Fig. 1C). No resistance conferring
mutations are observed in the sequences from the pre-HAART
era for the integrase protein (Fig. 1E). For the post-HAART data,
we observed many more amino acid replacements conferring
resistance to protease inhibitors, and these sequences were of-
ten clustered in the phylogenetic tree (Fig. 1B). Similar patterns
were seen for the reverse transcriptase and integrase proteins
(Fig. 1D and F). Comparable results were observed when the
phylogenetic analysis was repeated with all sites in the protein
sequence known to confer drug resistance removed, indicat-
ing that the patterns are not due to convergent evolution
(Supplementary Fig. S1).
Analysis of the sequence data sets showed that 85% of the
sequences containing drug resistance-associated mutations are
associated with up to three changes in protease (Fig. 2), and that
there is a significant correlation between the acquisition of drug
resistance associated mutation and the accumulation of associ-
ated non-drug resistance mutations (Pearson’s r¼ 0.5, p< 0.05).
For example, a sequence having as many as five drug resistance
mutations could be associated with as high as 14 non-resistant
mutations (Fig. 2). This pattern suggests that drug resistance oc-
curs randomly with more resistance conferring changes associ-
ated with more evolutionary change. Note that we are cautious
about over-interpreting any branch length differences. The drug
resistant viruses are presumably from uncontrolled infections
so are more likely to have been transmitted, and also to have
accumulated more variation (so exhibiting longer branches).
2.2 Structural analysis
In order to characterize the likely effects of variants on protein
function and viral fitness we mapped protein sequence changes
to the protein structure and characterized their impact. Using
maximum likelihood methods, we reconstructed the likely an-
cestral sequences for each node of the phylogenetic trees for
the data sampled from 1996 onwards. Using standard compara-
tive modelling techniques (Sali and Blundell 1993), we built
structural models of the inferred ancestral node sequences and
traced the likely evolutionary trajectory for each external node
containing at least one drug resistance-conferring amino acid
replacement.
The effect of amino acid replacements on protein stability
was predicted for all ancestral sequences in each trajectory us-
ing FoldX (Guerois et al. 2002). We find that the sequences in the
early parts of most trajectories are characterized by amino acid
replacements that have a neutral or stabilizing impact on the
protein structure (Figs 3 and 4). Examination of an example tra-
jectory for each protein (Fig. 5) shows that the later part of each
trajectory is categorized by a high frequency of destabilizing
mutations, and many of these replacements are associated with
drug resistance. We mapped the mutations occurring along all
mutational steps occurring in these evolutionary trajectories to
the HIV-1 protein structures. Interestingly, amino acid replace-
ments tend not to be found in close proximity to the resistance
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Figure 1. Phylogenetic trees showing the evolutionary history of HIV-1 subtype B sequences: pre-HAART/1996 protease sequences (A), post-HAART/1996 onwards pro-
tease sequences (B), pre-HAART/1996 reverse transcriptase sequences (C), post-HAART/1996 onwards reverse transcriptase sequences (D), pre-HAART/1996 integrase
sequences (E), and post-HAART/1996 onwards integrase sequences (F). The branches coloured red represent those sequences obtained from the Los Alamos HIV-1 se-
quence database that have at least one mutation conferring resistance to protease inhibitors (A & B), NRTIs/NNRTIs (C & D) and integrase inhibitors (E & F), whereas
those coloured black have no identified drug resistance mutations. The scale bar below each tree indicates the number of amino acid replacements per site.
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mutations, but instead are spread throughout the protein struc-
ture (Fig. 6).
In order to compare protein stability across the trajectories,
each was split into early, middle and late parts. Comparing
these parts for all trajectories, we find there is a general trend of
decreasing protein stability (Figs 7 and 8). Surprisingly, the
same trend is observed for the non-resistant lineages (Figs 7
and 8). Testing this, we find that there is a significant difference
(Mann–Whitney Test, p< 0.05) between the DDG values of the
early versus middle and middle verse late parts of the trajecto-
ries in both the resistant and non-resistant sequences for the
protease protein. The pattern is similar for reverse transcriptase
for early verse middle parts of the trajectories in both the re-
sistant and non-resistant sequences, and only significant for
the middle versus late parts for the non-resistant sequences
(p< 0.05).
These analyses were repeated with different random sam-
ples of trajectories (200 in total), and these showed similar
trends. To compare the replicate trajectory sets (Supplementary
Figs S4 and S5), we assessed the high-energy portions of the tra-
jectories by considering the 75th percentile values of all cumu-
lative energy values seen in each trajectory. For the trajectories
leading to drug resistance in the protease protein, we find that
the 75th percentile value does not exceed 4.56 kcal/mol across
the five samples, and the average of the 75th percentile across
the five samples was 3.47 kcal/mol. On the other hand, the resis-
tance trajectories for reverse transcriptase had a 75th percentile
value which does not exceed 8.67 kcal/mol, and the average of
the 75th percentile across the five samples was 6.92 kcal/mol.
The average of the 75th percentile across the five samples for
the non-resistance trajectories encountered in the protease pro-
tein was 2.35 and 6.48 kcal/mol for reverse transcriptase.
Although these findings confirm the tendency for significant
amino acid changes to destabilise the protein structure, they in-
dicate that there’s a general decrease in the protein stability
across HIV-1’s recent evolution. To check this pattern is not due
to the resistant and non-resistant variants sharing ancestry, we
repeated the analysis excluding the resistant sequences. Our re-
sults demonstrate that the trajectories were similarly character-
ized by early stabilizing mutations that precede destabilizing
mutations (data not shown). This must be a reflection of the ne-
cessity for the virus to escape the immune response via residue
replacements, and as such these non-resistant lineages cannot
be considered as controls as they are also under-going adaptive
evolution.
Finally, we estimated the probability of viral sequences fol-
lowing a pathway that will lead to the acquisition of drug resis-
tance. We find that certain nodes in some trajectories lead to
the development of resistance more frequently as indicated by
Figure 2. Heatmap plot showing the correlation between the frequency of drug
resistance mutations (counts of amino acid replacements) in a sequence and
the number of non-drug resistance mutations accumulated from 1996 onwards
in protease sequences. The y-axis indicates the frequency of non-drug resis-
tance mutations accumulated with respect to the number drug resistance muta-
tions, while the x-axis shows the number drug resistance mutations. The colour
of the square bins indicates the number of sequences in the data that have the
frequency of non-drug resistance associated mutations.
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Figure 3. Energy landscape showing trajectory energies for HIV-1 protease pro-
tein for both resistant and non-resistant sequences. Each trajectory is plotted in
grey, with frequently shared paths appearing to be darker. The red lines indicate
the step in resistance trajectories just before a resistance mutation is acquired
(indicated by the blue circles). The y-axis represents the predicted difference in
energy between each mutant and the wild-type strain (DDG). Each line on the
x-axis represents a mutational step between a parent and child node starting
from the first descendant of the most recent common ancestor. Note, the energy
changes are cumulative.
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Figure 4. Energy landscape showing a summary of trajectory energies for HIV-1
reverse transcriptase protein for both resistant and non-resistant sequences.
See Fig. 3 legend for details.
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higher probability scores (Figs 9 and 10). Sequences passing
through the ancestral nodes that carry a particular set of muta-
tions are therefore more likely to eventually acquire a drug re-
sistance mutation.
Because of the lack of a complete three-dimensional struc-
ture covering the whole length of the integrase protein, we in-
vestigated the degree to which amino acid replacements can be
tolerated in those positions in the partial structure where muta-
tions were observed. Using FoldX, we computed the energy
changes associated with the observed amino acid replacements
against a background distribution of energies of mutations to
the 19 other possible amino acids. We found that the change in
folding energies for the observed amino acid replacements were
mostly stabilizing or neutral with a small number that were
destabilizing. When compared to the background distributions
of the change in folding energies, the predicted effect of the ob-
served amino acid replacements were relatively small, meaning
that the observed replacements are likely to have minimal im-
pact on the stability of the HIV-1 integrase protein (Fig. 11).
However, for the few cases where the observed amino acid re-
placement energy value was above the upper quartile of the
energy distributions, we found that these replacements oc-
curred later in the evolutionary trajectories after the enabling
substitutions had occurred, confirming that stabilizing muta-
tions usually precede destabilizing ones.
3. Discussion
Collectively, our results indicate that drug resistance is con-
strained by fitness effects arising from protein structure, in a
similar way to protein stability constraints that need to be over-
come for immune escape to occur (Boutwell et al. 2013). This is
consistent with a subset of the resistance mutations that have
been tested experimentally by Chang and Torbett (2011). Their
analysis on both point and double mutants demonstrated that
the accumulation of drug resistance associated mutations
destabilises the HIV-1 protease protein. Chang and Torbett also
showed that specific non-drug resistant accessory mutations,
which are stabilizing, are acquired to stabilise the protein, sup-
porting our modelling results. Over the course of our evolution-
ary trajectories, the total energy change (cumulative DDG of
replacements) tends to be mostly neutral or positive for the
A B
Figure 5. Example landscape of the energy changes for each internal node in a trajectory that leads to a resistance mutation for HIV-1’s protease protein (A) and reverse
transcriptase protein (B). The y-axis represents the predicted difference in energy between each mutant and the wild-type strain (DDG). Each bar on the x-axis repre-
sents a mutational step between a parent and child node starting from the first descendant of the most recent common ancestor. The red bar indicates the node (step)
where the drug resistance conferring mutation occurred.
Figure 6. Structural context of the drug resistance mutations (amino acid replacements) occurring along an example trajectory in HIV-1’s protease protein, PDB code 1KZK
(A) and reverse transcriptase protein, PDB code 1RTJ (B), see Fig. 5 for trajectories. The resistance mutations for the protease (M46I and I84V) and reverse transcriptase are
coloured red. The catalytic aspartates are coloured purple. The various amino acid replacements occurring prior to the resistance mutation are shown in yellow.
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HIV-1 proteins, resulting in trajectories that are destabilizing
overall.
Interestingly, similar trajectories are observed in the non-
drug resistance lineages (Figs 3 and 4) indicating this type of
evolution is a normal part of HIV-1 evolution due presumably to
the need to accommodate otherwise deleterious/destabilizing
mutations in the context of on-going immune escape (Boutwell
et al. 2013). What is particularly interesting is this tendency for
viruses to have accumulated destabilizing mutations in an in-
fection will impact on their transmissibility such that
transmitted variants will tend to be ‘purged’ of destabilizing
mutations (Carlson et al. 2014). This would also explain why
drug resistance variants are often not successful when trans-
mitted or often revert when drug treatment is stopped
(Devereux et al. 1999; Verhofstede et al. 1999).
Crucially, the consequences of a missense mutation must be
assessed in the context in which it occurs. A mutation that is
deleterious in one context may be beneficial in another and this
will depend on the stability of the specific protein structure.
Furthermore, mutations may individually lead to beneficial
changes for one aspect of molecular function but may be delete-
rious with regard to another aspect. We have observed many
amino acid replacements of this type, in that they have the po-
tential to convey drug resistance but at the same time reduce
protein stability. Indeed most viral populations revert to wild-
type once drug pressure is removed (Devereux et al. 1999;
Verhofstede et al. 1999; Lawrence et al. 2003). For the beneficial
trait to become fixed in the population, it must occur in a con-
text where the deleterious trait does not lead to a drop in fitness
so severe that it represents an impassable valley in the fitness
landscape.
In HIV-1, we are thus observing the viable pathways in the
virus’ past evolution. These pathways depend on the existence
of enabling mutations that increase the protein stability where
resistance-associated mutations are later observed. Amino acid
replacements can have either stabilizing or destabilizing effects
on protein structures, and the magnitude of these changes can
be large (Tokuriki et al. 2007). A protein that is only marginally
stable can therefore accommodate only a small number of
amino acid replacements, since the majority of destabilizing re-
placements have the potential to result in an unfolded, non-
functional protein. Stabilizing replacements therefore have a
general enabling effect, since they increase the breadth of re-
placements that can be accommodated at other sites in the
protein.
The set of trajectories that lead to drug resistance will be
somewhat limited by the constraints arising from protein
structure, function, and energetics (Figs 9 and 10) and there
are substantial differences in the frequencies by which they
lead to drug resistance. Identification of these pathways to
resistance has the potential to permit the monitoring of viral
sequences with similar properties, that is, variants with a
raised probability of contributing to drug resistance. It is im-
portant to note that internal nodes on the tree have shared
history, and so they are not independent. As a result, the sta-
bility effect of some amino acid replacements will be shared
by some trajectories. This means that the stability effects in
one population are related to and/or influenced by that of
others. This non-independence is reflected in Figs 4 and 5 by
the shared trajectories, indicated by darker lines. This further
emphasises our finding that some evolutionary trajectories
are more easily followed than others.
The observed spatial distribution of enabling replacements,
spread throughout the protein structure, is further evidence of
the general nature of this effect. The alternative method of sta-
bilization, whereby a deleterious intramolecular interaction is
relieved by a specific compensating change at a spatially neigh-
bouring site, is rarely observed. Generally stabilizing mutations
are therefore enabling rather than directly epistatic. The fact
that these patterns are observed for both resistant and non-
resistant sequences confirms that the occurrence of enabling
mutations may represent a general mechanism of maintaining
evolvability (Tokuriki and Tawfik 2009). However, the cumula-
tive energy values of trajectories having drug resistance tend to
Figure 7. Box and whisker plots comparing the distributions of DDG values in
the protease protein for early, middle and late stages of the evolutionary trajec-
tories for all extant sequences for resistant and non-resistant sequences.
Figure 8. Box and whisker plots comparing the distributions of DDG values in
the reverse transcriptase protein for early, middle and late stages of the evolu-
tionary trajectories for all extant sequences for resistant and non-resistant
sequences.
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be higher than those of the non-resistance trajectories. This
may be indicative of the fact that the drug resistance conferring
change (i.e. adaptive mutations) are selected for because
they may be having a fitness/functional advantage thereby
compromising stability whereas other changes will not persist
if they are very destabilizing to the protein structure (Tokuriki
et al. 2008). Also the fact that drug resistance trajectories tend
to have more mutations than the non-resistance ones and be-
cause these mutations are additive, results in the energy values
tending to be higher (Serrano et al. 1993; Zhang et al. 1995).
The compensatory nature of stabilizing mutations has been
studied before in viruses (Bloom et al. 2010; Chang and Torbett
Figure 9. Energy landscape showing a summary of the cumulative energy changes for all trajectories including those leading to drug resistance in the HIV-1 protease
protein. The y-axis represents the predicted difference in energy between each mutant and the wild-type strain (DDG). Each line on the x-axis represents a mutational
step between a parent and child node starting from the first descendant of the most recent common ancestor. Each trajectory is terminated at the first mutational step
where a drug resistant mutation is detected. The red lines indicate the step in each trajectory just before a resistance mutation is acquired indicated by the blue circles.
The probability of a sequence leading to a resistance-associated mutation is shown (total number of sequence passing through that node is in parentheses). The proba-
bility of acquisition of a resistance mutation is calculated by dividing the total number of pathways passing through a node that ultimately acquire a resistance muta-
tion by the total number of pathways. For clarity values are omitted if fewer than five sequences pass through a node.
Figure 10. Energy landscape showing a summary of the cumulative energy changes for all trajectories including those leading to drug resistance in the HIV-1 reverse
transcriptase protein. See Fig. 9 legend for details.
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2011; Boutwell et al. 2013), and the generality of this evolu-
tionary process is confirmed by the observation of similar tra-
jectories in other systems, such as ribulose-1,5-bisphosphate
carboxylase (Gong et al. 2013; Studer et al. 2014), where either
neutral or stabilizing replacements were found to facilitate the
acquisition of new functions. Similar patterns have also been
observed in a number of enzymes from different organisms that
acquired new substrate specificities (Tokuriki et al. 2008).
Interestingly, we find no significant differences in the
spatial occurrence of amino acid replacements in HIV-1 Pol
structures when the pre-HAART sequences are compared with
post-HAART sequences. This demonstrates that while there is a
difference in the numbers of amino acid replacements (i.e. more
changes conferring resistance) before and after drug selection,
there is no difference in the pattern of amino acid replacements
on the protein structure. We have also shown that these pat-
terns are similar in other HIV-1 enzymes.
In conclusion, the high evolutionary rate of HIV-1 represents
a challenge for the development of effective treatments. Since
stabilizing mutations in the viral population tend to be en-
abling, they represent the first steps of a path to drug resistance,
especially in patients who are non-compliant with their drug
treatment. Moreover, since stabilizing mutations may enable a
wide range of subsequent mutations of any type, their occur-
rence in the viral population should be a cause for concern,
since they may allow the virus to evolve in a wide range of
unforeseeable directions that are unrelated to drug resistance,
such as immune escape. Fortunately, the constraints arising
from protein structure (Woo et al. 2010; Snoeck et al. 2011;
Williams et al. 2011) limit the ‘choice’ of evolutionary trajecto-
ries that the virus can take to acquire a resistance-causing
mutation.
4. Methods
The HIV-1 drug resistance information was obtained from the
Stanford HIV-1 Drug Resistance Database (Shafer 2006), while
the HIV-1 subtype B sequences analysed were obtained for the
Los Alamos HIV-1 Database (http://www.hiv.lanl.gov/). The
search parameters for the amino acid sequence downloads
from the Los Alamos HIV Sequence database were: sampling
country—US, subtype—B, genomic region—Protease, P51 (RT),
and P31 (Integrase). HIV-1 protein structures were obtained
from the Protein Data Bank (Berman et al. 2002) with the follow-
ing data information: protease, PDB code 1KZK (Reiling et al.
2002); reverse transcriptase, PDB code 1RTJ (Esnouf et al. 1995);
integrase, PDB code 1ITG (Dyda et al. 1994).
The HIV-1 sequences were split into two sets: (i) prior to
1996, derived before the advent of HAART and (ii) those col-
lected from 1996 onwards, after the widespread use of HAART.
After removal of identical sequences, those with internal stop
codons and/or undefined amino acids, a total of 649 (prior to
1996) and 4,434 (1996 onwards) sequences were analysed for the
protease protein. For the reverse transcriptase, a total of 219
(prior to 1996) and 912 (1996 onwards) sequences were analysed
while 105 (prior to 1996) and 737 (1996 onwards) sequences were
analysed for the HIV-1 integrase protein. The large size of the
1996-onward data sets (Supplementary Figs S2 and S3) made
the ancestral sequence inference computationally intractable,
so sequences were split into five sets of 200 randomly selected
sequences for both the HIV-1 protease and reverse transcrip-
tase. We maintained the proportion of sequences containing
drug resistance mutations in the samples to be consistent with
the original data.
The sequences were aligned and the phylogenetic trees were
predicted based on maximum likelihood methods implemented
in RAxML (Stamatakis 2014), using the WAG substitution model
(Whelan and Goldman 2001). Ancestral sequences of HIV-1 pro-
teins were reconstructed using FastML (Ashkenazy et al. 2012),
also using the maximum likelihood method and the WAG sub-
stitution model. The evolutionary trajectories of every sequence
containing at least one drug resistance-associated amino acid
replacement were traced to its most recent common ancestor.
The sequences of all internal nodes were compared with their
ancestors to identify amino acid replacements. The differences
between every consecutive pair of nodes were recorded. The
phylogenetic tree structure implies that trajectories share sub-
sets of these mutational steps, which can contain single or mul-
tiple changes. This information was used to compute the
probabilities of acquiring a resistance mutation, given a series
of observed changes, by counting the number of trajectories
sharing a series of changes that go on to either develop or not
develop drug resistance.
The structure of the most recent common ancestor of the se-
quences for each protein was predicted using Modeller (Sali and
Blundell 1993). The change in energy for amino acid replace-
ments was predicted using an empirical force field as imple-
mented in FoldX (Guerois et al. 2002) (version 3 Beta 6). Using
the ‘BuildModel’ function in FoldX and with the ‘vdw design’ pa-
rameter set to ‘0’ (Schymkowitz et al. 2005), we generated mu-
tant structures for all the sequences occurring in each
trajectory, and then predicted the change in energy for each
mutant. Because a complete structure for the integrase protein
was not available, in this case we conducted a separate analysis
using the most complete structure as follows: for every position
in which an amino acid replacement was observed, the native
amino acid residue in the ‘wild-type’ sequence was mutated to
the 19 other possible residues using the BuildModel function in
FoldX. The energy change for each observed mutation was also
predicted.
The probability of acquisition of a resistance mutation is cal-
culated by dividing the total number of pathways passing
through a node that ultimately acquire a resistance mutation by
the total number of pathways. For clarity values are omitted if
fewer than five sequences pass through a node. The calculation
of the probability of acquiring resistance mutation was done as
follows: once the ML tree and joint ancestral sequence
Figure 11. Analysis of mutations (amino acid replacements) in the context of
the HIV-1 integrase protein structure. Change in energy (DDG) for all amino acid
replacements found in regions of known protein structure, as predicted using a
statistical potential. Each boxplot represents a distribution of energy changes to
all 19 other residue types at positions where a non-synonymous substitution
has been observed. The DDG of the observed substitution is indicated in red.
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reconstruction have been performed, the mutational trajecto-
ries of each extant sequence can be followed up to the root of
the tree. The tree structure invariably means that extant se-
quences will share some internal nodes. Thus, for each internal
node, we can calculate the probability that any sequence having
that node on its trajectory will go on to acquire resistance-
conferring mutations at some point. Let N be the total number of
trajectories (resistance-associated or otherwise) passing through a
given internal node. Let NR be the number of these trajectories that
acquire resistance at any point downstream of the current node.
Then, we estimate the probability PR of acquiring resistance as:
PR ¼ NR=N
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